Basic Information
| RNALocate ID: | RLID:11000997 |
| RNA Symbol: | hsa-miR-100-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-100-5p |
| RNA ID: | miRBase:MIMAT0000098 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23382797 |
| Tissue/Cell Line: | Brain tissue |
| Method: | Microarray |
| Description: | We performed miRNA expression analysis using a FlexMAP3D instrument by (Luminex Corporation, Austin, TX) and a manufacturer's assay for 312 miRNA (Table S1). Data are collected from Table S1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001431 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01001432 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001433 | Mitochondrion | Cell line (HeLa) | 22984580 |
| RLID:01001434 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001435 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11000993 | Exosome | Human cervical cancer cell line (HeLa) | 25760330 |
| RLID:11000994 | Exosome | LAC cell line (A549) | 28553110 |
| RLID:11000995 | Exosome | Primary dendritic cells | 21505438 |
| RLID:11000996 | Exosome | Renal cancer cells | 21670082 |
| RLID:11000998 | Exosome | Plasma | 23663360 |
| RLID:11000999 | Exosome | Human esophageal cancer cell line (EC9706) | 25184951 |
| RLID:11001000 | Exosome | B cell lymphoma cell lines|EBV-transformed lymphoblastoid B cells | 25242326 |
| RLID:11001001 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11001002 | Microvesicle | Hepatoma cells | 23771658 |
| RLID-D:11000032 | Exosome | Blood|Breast tissue|Colon tissue|Endothelial cells|Epithelial cells|Seminal fluid|Tongue tissue | |
| RLID-D:11000297 | Microvesicle | Blood|Breast cell line|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-100-5p | Diffuse large b cell lymphoma | MNDR-E-MI-02417 |
| MNDR | hsa-miR-100-5p | Mantle cell lymphoma | MNDR-E-MI-02418 |
| MNDR | hsa-miR-100-5p | Splenic marginal zone lymphoma | MNDR-E-MI-02419 |
| MNDR | hsa-miR-100-5p | Colorectal adenoma | MNDR-E-MI-02420 |
| MNDR | hsa-miR-100-5p | Oral squamous cell carcinoma | MNDR-E-MI-02421 |
| MNDR | hsa-miR-100-5p | Large cell neuroendocrine cancer | MNDR-E-MI-02422 |
| MNDR | hsa-miR-100-5p | Medulloblastoma | MNDR-E-MI-02423 |
| MNDR | hsa-miR-100-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-02424 |
| MNDR | hsa-miR-100-5p | Ovarian clear cell carcinoma | MNDR-E-MI-02425 |
| MNDR | hsa-miR-100-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-02426 |
| MNDR | hsa-miR-100-5p | Lymphoma | MNDR-E-MI-02427 |
| MNDR | hsa-miR-100-5p | Lymphoma non-hodgkin | MNDR-E-MI-02428 |
| MNDR | hsa-miR-100-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-02429 |
| MNDR | hsa-miR-100-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-02430 |
| MNDR | hsa-miR-100-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-02431 |
| MNDR | hsa-miR-100-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-02432 |
| MNDR | hsa-miR-100-5p | Her2-receptor positive breast cancer | MNDR-E-MI-02433 |
| MNDR | hsa-miR-100-5p | Breast cancer luminal | MNDR-E-MI-02434 |
| MNDR | hsa-miR-100-5p | Niemann-pick disease type c | MNDR-E-MI-02435 |
| MNDR | hsa-miR-100-5p | Prostate cancer | MNDR-E-MI-02436 |
| MNDR | hsa-miR-100-5p | Gastric cancer | MNDR-E-MI-02437 |
| MNDR | hsa-miR-100-5p | Gastric lymphoma | MNDR-E-MI-02438 |
| MNDR | hsa-miR-100-5p | Alzheimer disease | MNDR-E-MI-02439 |
| MNDR | hsa-miR-100-5p | Intracranial aneurysm | MNDR-E-MI-02440 |
| MNDR | hsa-miR-100-5p | Bladder cancer | MNDR-E-MI-02441 |
| MNDR | hsa-miR-100-5p | Esophageal carcinoma | MNDR-E-MI-02442 |
| MNDR | hsa-miR-100-5p | Dysautonomia familial | MNDR-E-MI-02443 |
| MNDR | hsa-miR-100-5p | Myotonic dystrophy | MNDR-E-MI-02444 |
| MNDR | hsa-miR-100-5p | Head and neck cancer | MNDR-E-MI-02445 |
| MNDR | hsa-miR-100-5p | Ataxia telangiectasia | MNDR-E-MI-02446 |
| MNDR | hsa-miR-100-5p | Huntington disease | MNDR-E-MI-02447 |
| MNDR | hsa-miR-100-5p | Chorea | MNDR-E-MI-02448 |
| MNDR | hsa-miR-100-5p | Cardiovascular disease | MNDR-E-MI-02449 |
| MNDR | hsa-miR-100-5p | Lung cancer | MNDR-E-MI-02450 |
| MNDR | hsa-miR-100-5p | Biliary atresia | MNDR-E-MI-02451 |
| MNDR | hsa-miR-100-5p | Down syndrome | MNDR-E-MI-02452 |
| MNDR | hsa-miR-100-5p | Parkinson disease | MNDR-E-MI-02453 |
| MNDR | hsa-miR-100-5p | Colonic adenomas | MNDR-E-MI-02454 |
| MNDR | hsa-miR-100-5p | Basal-like breast cancer | MNDR-E-MI-02455 |
| MNDR | hsa-miR-100-5p | Pancreatic cancer | MNDR-E-MI-02456 |
| MNDR | hsa-miR-100-5p | Melanoma | MNDR-E-MI-02457 |
| MNDR | hsa-miR-100-5p | Epithelial ovarian cancer | MNDR-E-MI-02458 |
| MNDR | hsa-miR-100-5p | Colon cancer | MNDR-E-MI-02459 |
| MNDR | hsa-miR-100-5p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-02460 |
| MNDR | hsa-miR-100-5p | Ovarian cancer | MNDR-E-MI-02461 |
| MNDR | hsa-miR-100-5p | Prostate adenocarcinoma | MNDR-E-MI-02462 |
| MNDR | hsa-miR-100-5p | Carcinoma ductal breast | MNDR-E-MI-02463 |
| MNDR | hsa-miR-100-5p | Glioblastoma | MNDR-E-MI-02464 |
| MNDR | hsa-miR-100-5p | Astrocytoma | MNDR-E-MI-02465 |
| MNDR | hsa-miR-100-5p | Glioma | MNDR-E-MI-02466 |
| MNDR | hsa-miR-100-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-02467 |
| MNDR | hsa-miR-100-5p | Chordoma | MNDR-E-MI-02468 |
| MNDR | hsa-miR-100-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-02469 |
| MNDR | hsa-miR-100-5p | Temporal lobe epilepsy | MNDR-E-MI-02470 |
| MNDR | hsa-miR-100-5p | Osteosarcoma | MNDR-E-MI-02471 |
| MNDR | hsa-miR-100-5p | Carotid artery thrombosis | MNDR-E-MI-02472 |
| MNDR | hsa-miR-100-5p | Breast carcinoma | MNDR-E-MI-02473 |
| MNDR | hsa-miR-100-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-02474 |
| MNDR | hsa-miR-100-5p | Meningioma | MNDR-E-MI-02475 |
| MNDR | hsa-miR-100-5p | Uterine cancer | MNDR-E-MI-02476 |
| MNDR | hsa-miR-100-5p | Cervical adenocarcinoma | MNDR-E-MI-02477 |
| MNDR | hsa-miR-100-5p | Gastric adenocarcinoma | MNDR-E-MI-02478 |
| MNDR | hsa-miR-100-5p | Cervical squamous cell carcinoma | MNDR-E-MI-02479 |
| MNDR | hsa-miR-100-5p | Pituitary adenoma | MNDR-E-MI-02480 |
| MNDR | hsa-miR-100-5p | Lung squamous cell carcinoma | MNDR-E-MI-02481 |
| MNDR | hsa-miR-100-5p | Non-small cell lung cancer | MNDR-E-MI-02482 |
| MNDR | hsa-miR-100-5p | Lung adenocarcinoma | MNDR-E-MI-02483 |
| MNDR | hsa-miR-100-5p | Adrenocortical carcinoma | MNDR-E-MI-02484 |
| MNDR | hsa-miR-100-5p | Thyroid carcinoma | MNDR-E-MI-02485 |
| MNDR | hsa-miR-100-5p | Ovarian carcinoma | MNDR-E-MI-02486 |
| MNDR | hsa-miR-100-5p | Bladder urothelial carcinoma | MNDR-E-MI-02487 |
| MNDR | hsa-miR-100-5p | Bladder carcinoma | MNDR-E-MI-02488 |
| MNDR | hsa-miR-100-5p | Skin cancer | MNDR-E-MI-02489 |
| MNDR | hsa-miR-100-5p | Intrastent restenosis | MNDR-E-MI-02490 |
| MNDR | hsa-miR-100-5p | Cervical cancer | MNDR-E-MI-02491 |
| MNDR | hsa-miR-100-5p | Carcinoma renal cell | MNDR-E-MI-02492 |
| MNDR | hsa-miR-100-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-02493 |
| MNDR | hsa-miR-100-5p | Renal clear cell carcinoma | MNDR-E-MI-02494 |
| MNDR | hsa-miR-100-5p | Biliary tract cancer | MNDR-E-MI-02495 |
| MNDR | hsa-miR-100-5p | Adenocarcinoma of esophagus | MNDR-E-MI-02496 |
| MNDR | hsa-miR-100-5p | Cholangiocarcinoma | MNDR-E-MI-02497 |
| MNDR | hsa-miR-100-5p | Esophageal cancer | MNDR-E-MI-02498 |
| MNDR | hsa-miR-100-5p | Liver cirrhosis | MNDR-E-MI-02499 |
| MNDR | hsa-miR-100-5p | Lung small cell carcinoma | MNDR-E-MI-02500 |
| MNDR | hsa-miR-100-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-02501 |
| MNDR | hsa-miR-100-5p | Myocardial infarction | MNDR-E-MI-02502 |
| MNDR | hsa-miR-100-5p | Adenoma | MNDR-E-MI-02503 |
| MNDR | hsa-miR-100-5p | Breast invasive carcinoma | MNDR-E-MI-02504 |
| MNDR | hsa-miR-100-5p | Early hepatocellular carcinoma | MNDR-E-MI-02505 |
| MNDR | hsa-miR-100-5p | B-cell lymphoma | MNDR-E-MI-02506 |
| MNDR | hsa-miR-100-5p | Rheumatoid arthritis | MNDR-E-MI-02507 |
| MNDR | hsa-miR-100-5p | T-cell leukemia | MNDR-E-MI-02508 |
| MNDR | hsa-miR-100-5p | Malignant pleural mesothelioma | MNDR-E-MI-02509 |
| MNDR | hsa-miR-100-5p | Neuroblastoma | MNDR-E-MI-02510 |
| MNDR | hsa-miR-100-5p | Barrett's adenocarcinoma | MNDR-E-MI-02511 |
| MNDR | hsa-miR-100-5p | Hodgkin lymphoma | MNDR-E-MI-02512 |
| MNDR | hsa-miR-100-5p | Burkitt lymphoma | MNDR-E-MI-02513 |
| MNDR | hsa-miR-100-5p | Tonsil cancer | MNDR-E-MI-02514 |
| MNDR | hsa-miR-100-5p | Skin cutaneous melanoma | MNDR-E-MI-02515 |
| MNDR | hsa-miR-100-5p | Skin melanoma | MNDR-E-MI-02516 |
| MNDR | hsa-miR-100-5p | Acute myeloid leukemia | MNDR-E-MI-02517 |
| MNDR | hsa-miR-100-5p | Colorectal cancer | MNDR-E-MI-02518 |
| MNDR | hsa-miR-100-5p | Multiple myeloma | MNDR-E-MI-02519 |
| MNDR | hsa-miR-100-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-02520 |
| MNDR | hsa-miR-100-5p | Ependymoma | MNDR-E-MI-02521 |
| MNDR | hsa-miR-100-5p | Nasopharyngeal cancer | MNDR-E-MI-02522 |
| MNDR | hsa-miR-100-5p | Sleep deprivation | MNDR-E-MI-02523 |
| MNDR | hsa-miR-100-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-02524 |
| MNDR | hsa-miR-100-5p | Pancreatitis chronic | MNDR-E-MI-02525 |
| MNDR | hsa-miR-100-5p | Barrett's carcinogenesis | MNDR-E-MI-02526 |
| MNDR | hsa-miR-100-5p | Breast cancer her3+ negative | MNDR-E-MI-02527 |
| MNDR | hsa-miR-100-5p | High grade dysplastic nodule | MNDR-E-MI-02528 |
| MNDR | hsa-miR-100-5p | HPV | MNDR-E-MI-02529 |
| MNDR | hsa-miR-100-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-02530 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ACKR3 | Homo sapiens | RR00034282 |
TOP